Thursday, June 14, 2012
Two U.S. groups have developed platforms that could improve
the identification of cancer drug combinations that address drug resistance. A
team from The University of North Carolina at Chapel Hill School of
Medicine is using chemical proteomics to rationally
design kinase inhibitor combinations that block signaling pathways mediating
drug resistance,1 whereas Massachusetts Institute of Technology
researchers are screening for targeted therapeutics that sensitize cancer cells
to DNA-damaging agents when given sequentially rather than simultaneously.2
Kotz, J. SciBX 5(24);
Published online June 14, 2012
1. Duncan, J.S. et al. Cell; published online April 13, 2012;
Contact: Gary L. Johnson, The University of North Carolina at
Chapel Hill School of Medicine, Chapel Hill, N.C.
2. Lee, M.J. et al. Cell; published online May 11, 2012;
Contact: Michael B. Yaffe, Massachusetts Institute of
Technology, Cambridge, Mass.
AND INSTITUTIONS MENTIONED
Array BioPharma Inc.
(NASDAQ:ARRY), Boulder, Colo.
Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan
AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.
(Xetra:BAYN), Leverkusen, Germany
Cancer Research UK, London, U.K.
Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan
Dana-Farber Cancer Institute, Boston, Mass.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
The Institute of Cancer Research, Sutton, U.K.
Massachusetts Institute of Technology, Cambridge, Mass.
Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), Cambridge, Mass.
Onyx Pharmaceuticals Inc. (NASDAQ:ONXX), South San Francisco, Calif.
(SIX:ROG; OTCQX:RHHBY), Basel, Switzerland
The University of North Carolina at Chapel Hill School of
Medicine, Chapel Hill,